Abstract 94P
Background
Treatment strategies and prognoses of patients with metastatic colorectal cancer (CRC) differ according to the sidedness of the primary tumor. Recently, TP53 gain-of-function (GOF) and non-GOF variants have been reported to be differentially associated with prognosis by sidedness. We aimed to evaluate the sidedness-dependent prognostic impact of gene alterations in metastatic CRC.
Methods
SCRUM-Japan GI-SCREEN is a comprehensive genome screening project for gastrointestinal cancer that uses next-generation sequencing. Among patients diagnosed with metastatic CRC enrolled from April 2017 to March 2019, 531 who underwent complete gene sequencing were assessed. Patients whose tumor tissues were obtained after chemotherapy and who were enrolled more than six months after the initiation of first-line chemotherapy were excluded.
Results
Overall survival significantly differed between left-sided CRC and right-sided colon cancer (CC) in the TP53 non-GOF variant, KRAS wild-type, NOTCH1 wild-type, NOTCH1 covariant, NOTCH3 sole variant without the covariant of NOTCH1 or NOTCH2, and MYC amplification. Multivariate analysis in each side revealed that TP53 GOF and KRAS variants were independent prognostic factors for poorer prognosis in left-sided CRC [hazard ratio (HR) 1.51, 95% confidence interval (CI) 1.04–2.20, P = 0.03, and HR 1.48, 95% CI 1.11–1.96, P < 0.01, respectively], while TP53 non-GOF variant, BRAF V600E, and MYC amplification in right-sided CC (HR 1.56, 95% CI 1.01–2.40, P < 0.05, HR 2.56, 95% CI 1.41–4.64, P < 0.01, and HR 2.29, 95% CI 1.17–4.51, P = 0.02, respectively). NOTCH3 sole variant was an independent prognostic factor for improved prognosis in left-sided CRC (HR 0.30, 95% CI 0.15–0.62, P < 0.01).
Conclusions
The prognostic significance of gene alterations differed between left-sided CRC and right-sided CC. These are candidate stratification factors for clinical trials on the distinct sidedness of metastatic CRC and warrant further investigation.
Clinical trial identification
Editorial acknowledgement
We would like to thank Editage (www.editage.com) for English language editing.
Legal entity responsible for the study
The authors.
Funding
SCRUM-Japan.
Disclosure
T. Kajiwara: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. T. Nishina: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd. R. Yamashita: Financial Interests, Personal, Expert Testimony: Takeda Pharmaceutical Co., Ltd. Y. Nakamura: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Guardant Health AMEA; Financial Interests, Institutional, Funding: Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics; Financial Interests, Institutional, Coordinating PI: Seagen. S. Yuki: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Bristol Myers Squibb K.K., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., MSD K.K., Merck Biopharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd. H. Taniguchi: Financial Interests, Personal, Invited Speaker: Ono, Takeda, Eli Lilly, Chugai, Taiho, Merck Biopharma; Financial Interests, Institutional, Coordinating PI: Takeda, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Ono. H. Hara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, MSD, Ono, Bayer, Chugai, Lilly, Merck Biopharma, Taiho, Takeda, Yakult, Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI: Amgen, Astellas, AstraZeneca, Bayel, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono, Taiho, ALX oncology. T. Ohta: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb Japan, Chugai Pharma, Teijin Pharma, Takeda Pharmaceutical Company Limited., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Yakult Honsha, MSD K.K., Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Daiichi Sankyo COMPANY, LIMITED., Merck & Co., Ono Pharmaceutical CO., LTD.; Financial Interests, Personal and Institutional, Coordinating PI: Takeda Pharmaceutical Company Limited. T. Esaki: Financial Interests, Institutional, Research Grant: MSD K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., IQVIA Services Japan K.K., Syneos Health Inc., Chugai Pharmaceutical Co., Ltd., Amgen K.K., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Asahi Kasei Pharma Corporation; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., MSD K.K. E. Shinozaki: Financial Interests, Personal, Invited Speaker: Guardant Health Japan Corp. A. Takashima: Financial Interests, Institutional, Research Grant: MSD K.K., Amgen K.K., Bristol Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.; Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd. Y. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb K.K., Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd., Taiho Pharmaceutical Co., Ltd., Nihon Servier Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Incyte Biosciences Japan G.K. K. Yamazaki: Financial Interests, Personal, Invited Speaker: Chugai Pharma, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Lilly, Sanofi, Ono Pharmaceutical, MSD, Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Taiho Pharmaceutical. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd, Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd. I. Hyodo: Financial Interests, Personal, Advisory Board: Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract